Piramal Critical Care (PCC), a division of Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), today, announced the U.S. launch of Chlorpromazine Hydrochloride for Injection, USP, which will be offered in 25mg/1mL and 50mg/2 mL vials. With this launch, PCC continues to expand their generic injectables portfolio.
Peter DeYoung, Chief Executive Officer, Piramal Global Pharma commented: "We are excited to launch Chlorpromazine Hydrochloride for Injection, USP, which joins our growing US portfolio of injectable products at Piramal Critical Care. It further complements our market-leading inhaled anesthesia products, as we strive to deliver critical care solutions to patients and healthcare providers around the world."
The launch of Chlorpromazine Hydrochloride for Injection, USP (25mg/1mL and 50mg/2 mL vials) is the latest in a series of recent product launches from Piramal Cri?cal Care in the generic injectables market. In 2024, PCC launched the first to market generic of Edaravone IV Infusion, which followed 2023 launches of Pantoprazole Sodium for Injection, USP and Doxycycline for Injection, USP to further enhance their wide por?olio of critical care products.
Shares of Piramal Pharma Limited was last trading in BSE at Rs. 239.75 as compared to the previous close of Rs. 242.65. The total number of shares traded during the day was 280017 in over 4314 trades.
The stock hit an intraday high of Rs. 252.05 and intraday low of 238.75. The net turnover during the day was Rs. 68716522.00. |